Background and Purpose: Microvascular perfusion defects occur after occlusion and reperfusion of the middle cerebral artery in examples of focal cerebral ischemia. In addition to cellular (eg, polymorphonuclear leukocyte) contributors to the focal "no-reflow" phenomenon, activation of coagulation may also play a role. We have tested a potential role of tissue factor-mediated coagulation in the microvascular perfusion defects seen after focal cerebral ischemia-reperfusion in a baboon model of reversible middle cerebral artery occlusion with the murine anti-tissue factor monoclonal antibody TF9-6B4. Tissue factor is the principal resident procoagulant substance in cerebral tissues and has a distinct perivascular distribution.
I ncomplete perfusion of the microvasculature after transient focal or global cerebral ischemia and reperfusion constitutes the "no-reflow" phenomenon.1 Polymorphonuclear (PMN) leukocytes2-7 and platelets,8 in addition to other endothelium-and subendothelium-related mechanisms,9-11 have been implicated in the formation of these perfusion defects. In addition to cellular contributors to the microvascular perfusion defects after focal cerebral ischemia-reperfusion, coagulation system activation may play a role. This was initially suggested by the ability of the combination of heparin and ticlopidine to significantly reduce postischemia-reperfusion microvascular occlusion formation and platelet deposition in a nonhuman primate model. 12 The potent endogenous procoagulant, tissue factor (TF), found prominently in cerebral tissues13 and on perivascular cells,13-'5 may be an additional contributor to the development of microvascular occlusions. TF is a 30-kD glycosylated transmembrane protein expressed by epithelia and selected other cells, including vascular adventitial fibroblasts. It is the high-affinity receptor for factors VII and Vlla and is the cofactor necessary for the catalytic function of factor VIIa. 16 Binding of factor VII or VIIa to TF is Ca`dependent, and the TF-factor Vlla complex has been shown to be the major initiator of the coagulation cascade.17 '8 In addition, factors X and IX are activated by the TF-factor VIIa complex, thereby catalyzing thrombin generation and fibrin formation.17'920 TF is the principal procoagulant within brain tissue, where it has a prominent perivascular distribution around noncapillary cerebral microvessels (>10 ,gm in diameter), especially in gray matter.1315
Although information is scant, electron microscopy has demonstrated fibrin in microvessels associated with degranulated platelets and PMN leukocytes but not in capillaries, after middle cerebral artery (MCA) occlusion and reperfusion.2 The exposure of TF to the plasma column during vascular ischemia may contribute to intravascular coagulation and post-ischemia-reperfusion perfusion defects.
To test the hypothesis that TF-mediated fibrin formation may contribute to the no-reflow phenomenon in focal cerebral ischemia, a well-defined, endotoxin-free, murine, anti-human TF monoclonal antibody (MoAb), Preparation of the nonhuman primate model of right MCA occlusion and reperfusion and surgical implantation of the MCA occlusion device (Mentor Corporation, Goleta, Calif) have been described in detail.2,3'12 Halothane anesthesia was administered as 3% to 5% induction followed by 1.5% to 2.0% maintenance. After surgical recovery, all animals were allowed a 7-day interval before entry into the experimental protocol. All animals entered into the study were clinically free of infection or apparent inflammation and had normal neurological function (score, 100).
In this randomized open study, six animals received 10 mg/kg TF9-6B4 by intravenous infusion 10 minutes before MCA occlusion, and six animals received no intervention and served as a control group. All subjects were awake. The right MCA (25 mm2) from each section were processed automatically and in a blinded fashion as previously described.2 An identical number of fields were evaluated from each of the paired basal ganglia such that 2000 vessels in the left control basal ganglia were analyzed in each subject. Reproducibility and reliability data have been reported previously. 2 The ratio of all microvessels in the left (normal) basal ganglia to the left temporal cortex (layers I to VI) were 0.59+0.27 (n=6) and 0.60+0.23 (n=6) for control and treated animals, respectively, which compares favorably with previous observations.2,3
Relative microvascular patency was expressed as "percent reflow," the ratio of the number of carboncontaining microvessels in the ischemic to control basal ganglia normalized per 1.0 cm2 and expressed per 100 vessels.3 Accepted definitions of microvascular size were used for data analysis of discrete vessel size classes. 22, 23 Neurological function was assessed according to the weighted (100-point) scale suggested by Spetzler and colleagues.2,3,12,24 TF9-6B4 was purified from cell culture by protein A affinity chromatography in the following manner. The culture supernatant was diluted 1:1 with binding buffer (0.1 M glycine and 3 M NaCl, pH 8.9) and passed over a protein A (IPA 300, Repligen, Boston, Mass) column to bind murine immunoglobulin (Ig) G. Antibody was eluted with 50 mM acetate and 100 mM NaCl (pH 4.0). Elution was monitored by UV absorbance. The protein A column eluate was loaded onto a G-25 sepharose (Pharmacia, Stockholm, Sweden) column equilibrated with 50/50 phosphate-buffered saline (PBS) buffer (50 mM phosphate and 50 mM NaCl, pH 7.0) to exchange buffers. After buffer exchange, the antibody was filterconcentrated to 5 to 6 mg/mL using a Membrex Benchmark rotary biopurification system. MoAb in 50/50 buffer was then passed over DEAE Sepharose FF (Pharmacia) in nonbonding mode to reduce lipopolysaccharide and DNA contamination. The final product was sterilized by filtration through a 0.2-,um filter. The TF9-6B4 product was more than 90% pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis and had endotoxin levels less than 2 EU/mL by standard Limulus Plasma murine MoAb levels were significantly elevated over baseline within 10 minutes of infusion, reached a peak level within 1 hour, and remained elevated throughout the ischemia-reperfusion period (Fig 1) .
After 180 minutes of MCA occlusion and 60 minutes of reperfusion, the untreated group displayed a significant reduction in the number of patent lenticulostriatal microvessels with minimum diameters of 4.0 to 7.5 gm (P=.003) and 7.5 to 30.0 ,um (P=.018) in the ischemic compared with the nonischemic basal ganglia (Fig 2) . These vessels are consistent with capillaries and with postcapillary venules and precapillary arterioles, respectively. In contrast, the anticipated reduction in number of patent microvessels less than 30.0 gm in diameter in the ischemic territory was not observed in the TF9-6B4-treated cohort (P>.20) (Fig 3) . (connecting venules and small arterioles) (P=.013). A nonsignificant increase (P=.118) in reflow after TF9-6B4 was seen in capillaries (4.0 to 7.5 gm in diameter). The normalized patency difference (percent reflow) in microvessels in the size class of greater than 50 ,um in diameter was not significant because of the small number of vessels (16±12 cm-2 for control subjects and 37±19 cm-2 for treated subjects) contained in this size class and the variable percent reflow noted among subjects. The relatively small numbers of vessels in the 30.0-to 50.0-gm-diameter and the greater than 50.0-gm-diameter ranges may have influenced the results.
Parenchymal hemorrhage was not a feature of the TF9-6B4-treated group. Hemorrhagic infarction, seen in four of the six treated subjects, was not different from two events seen in the untreated group. Motor function measured by neurological assessment score declined within 5 to 15 minutes of MCA occlusion in all animals and remained unchanged for the duration of each experiment ( Table 1 ). The neurological score in animals treated with TF9-6B4 did not improve in the untreated group at any time during the ischemia and reperfusion period.
To evaluate any contribution of microvascular dilatation to the reflow improvement observed in the TF9-6B4 group, the normalized proportion of microvessels in each size class was determined at 1-,um intervals. The mean proportion of microvessels at each interval was nearly identical between the treated and untreated groups. Discussion Little attention has been focused on the role of fibrin formation, or other consequences of local thrombin generation, in microvascular obstruction after focal diameter distribution in the nonischemic MCA territories argues strongly against vasodilation as a contributor to perfusion enhancement by TF9-6B4.
These studies address the hypothesis that microvascular perfusion defects observed after temporary occlusion of the MCA may result from thrombosis within the microvasculature, either as a consequence of ischemic vascular injury, reperfusion, or both. The findings here support this hypothesis and indicate that fibrin formation is initiated at the earliest step perfusion defects has also been suggested by a significant reduction of postreperfusion occlusions after preischemia heparin and ticlopidine in the baboon model12 and a similar effect after heparin exposure in a 4-hour MCA occlusion-reperfusion macaque model.27 Separately, preischemia infusion of a novel antithrombin in a rodent forebrain ischemia model was shown to decrease microvascular occlusion formation after reperfusion. 40 We cannot exclude that among cells classified as PMN leukocytes in a recent report,2 a small number of monocytes may have been present, which also contributed to occlusion formation after focal ischemia-reperfusion in the primate.
The anti-TF MoAb TF9-6B4 has been shown to inhibit 96% of plasma coagulation induced by purified human brain TF.21 Similar inhibition of coagulation by TF9-6B4 was found using baboon brain extract as a source of the TF. Complete inhibition of coagulation and factor X activation was seen with anti-TF antibody concentrations on the order of 1 gg/mL in vitro. 21 Considering an average baboon plasma volume of 500 mL (10 kg) and a TF9-6B4 dose of 10 mg/kg, a concentration of approximately 500 ,ug/mL appears sufficient to achieve complete inhibition of TF activity. This is consistent with the plasma anti-TF antibody levels measured here.
The use of an anti-TF antibody to block TF-dependent coagulation carries a theoretically increased risk of parenchymal hemorrhage, especially in focal ischemia. The increased presence of TF in cerebral gray matter parenchyma may protect this territory from such expansive hemorrhages. In this study, no parenchymatous hematoma was seen in either group and hemorrhagic infarction, a natural consequence of focal cerebral ischemia and reperfusion, was not different from the untreated group. Because vascular permeability and hemorrhage may be related to ischemia duration, more prolonged MCA occlusion in the presence of TF9-6B4 may lead to significant intracerebral hemorrhage.
As with previous experiments,3 although microvascular patency was significantly improved after TF9-6B4 infusion, the short-term nature of this study did not afford an adequate assessment of neurological recovery. Therefore, long-term studies will be necessary to further clarify a role of this approach in stroke management.
In addition to a role of PMN leukocyte adherence,2,3 we describe here a second important potential contributor to impaired microvascular reflow after focal ischemia-reperfusion. The preischemia use of TF9-6B4 does not allow one to determine when TF-dependent fibrin formation may have occurred. The experimental paradigm used in this study maximized the vascular distribution and early effect of TF9-6B4 by infusion before MCA occlusion. At what point during ischemia or reperfusion TF may contribute to such perfusion defects remains to be elucidated.
